Sandostatin® LAR® (octreotide acetate suspension for injection) demonstrated antitumor benefit in patients with metastatic neuroendocrine tumors (NETs) of the midgut, according to interim data presented recently at the 2009 Gastrointestinal Cancer Symposium of the American Society of Clinical Oncology.
Original Article: New Study First To Confirm Sandostatin® LAR® Controls Tumor Growth In Patients With Rare Gastrointestinal Tumors
NEXT ARTICLE